Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FULFIL: FF/UMEC/VI vs Budesonide/Formoterol in Advanced COPD
NCT02345161Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2015
- Primary completion
- Apr 2016
- Modality
- Orthosteric Ligands
- Countries
- 15
01
Overview
A Phase 3 trial of fluticasone, umeclidinium, vilanterol in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started Jan 2015; status: completed.
02
Drugs
fluticasoneumeclidiniumvilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02345161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02345161.